Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
RYZ-101 by RayzeBio for Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET): Likelihood of Approval
RYZ-101 is under clinical development by RayzeBio and currently in Phase III for Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET). According to GlobalData,...
Data Insights
Risk adjusted net present value: What is the current valuation of Bristol-Myers Squibb's RYZ-101?
RYZ-101 is a synthetic peptide commercialized by Bristol-Myers Squibb, with a leading Phase III program in Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET)....